Peptides for Heart Failure: How SS-31, Apelin-13 & BPC-157 Are Revolutionizing HFpEF Treatment in 2026

Heart failure with preserved ejection fraction (HFpEF) is defined by the clinical syndrome of heart failure with a left ventricular ejection fraction ≥50% — meaning the heart's squeezing function appears normal on imaging, but something is deeply wrong with how the heart fills between beats.

The numbers are significant: HFpEF accounts for approximately 50% of all heart failure diagnoses, representing roughly 32 million patients globally. In the United States alone, approximately 3 million people develop HFpEF annually, and the incidence is rising as obesity, hypertension, and diabetes — the three biggest risk factors — become more prevalent. Cardiovascular mortality is 26%; annual all-cause mortality is 15%; rehospitalization within 5 years of first admission reaches 80%. ^[9]

Why HFpEF is uniquely difficult to treat:

• It is not pump failure. Traditional heart failure drugs target systolic dysfunction — a heart too weak to push blood out. In HFpEF, the pump works; the problem is diastolic stiffness that prevents proper filling between contractions.
• It is a syndrome, not a single disease. Cardiologists now recognize at least 4–5 distinct HFpEF phenotypes (obese HFpEF, inflammatory HFpEF, atrial fibrillation-associated HFpEF, etc.) each with different underlying mechanisms — making a single treatment unlikely to work for everyone.
• The trials kept failing. Drugs proven in reduced-EF heart failure showed neutral or harmful results in multiple HFpEF RCTs — suggesting the underlying biology is fundamentally different.

Two breakthroughs in the last three years changed the calculus: SGLT2 inhibitors (empagliflozin, EMPEROR-Preserved 2022) ^[2] and GLP-1 receptor agonists (semaglutide, STEP-HFpEF 2024) ^[1] both demonstrated meaningful clinical benefit in HFpEF — the first drug classes ever to do so in large randomized controlled trials. These successes opened the door to a new mechanistic understanding: HFpEF is at its core a disease of energy metabolism and inflammation, not merely structural stiffness.

That reframing is precisely why peptides — particularly mitochondrially-targeted ones — now command serious clinical attention.

The heart is the most metabolically demanding organ in the human body. At rest, it consumes approximately six kilograms of ATP per day — more than any other tissue per unit mass. To produce this energy, cardiomyocytes (heart muscle cells) are packed with mitochondria: these organelles make up roughly 30% of the total volume of each heart cell. The heart is essentially an ATP-burning machine, and its mitochondria are the engine.

In HFpEF, something goes catastrophically wrong in these powerhouses. Multiple converging lines of evidence now implicate mitochondrial dysfunction as a central driver — not merely a downstream consequence — of HFpEF pathophysiology: ^[3,4]

• ATP depletion: Cardiac energy supply falls relative to demand. Even at rest, HFpEF hearts show reduced ATP:ADP ratios and depleted phosphocreatine stores — an energy deficit that directly impairs relaxation.
• Reactive oxygen species (ROS) overproduction: Dysfunctional electron transport chains leak electrons to form reactive oxygen species. This oxidative stress damages contractile proteins, inflames the myocardium, and stiffens the extracellular matrix through collagen cross-linking.
• Mitochondrial fragmentation: Healthy mitochondria form elongated, interconnected networks (fusion). In HFpEF, they fragment into smaller, less efficient units (fission dysregulation) — a shift that reduces ATP output and increases apoptotic signaling.
• Cardiolipin dysfunction: Cardiolipin is a phospholipid unique to the inner mitochondrial membrane, essential for organizing the electron transport chain complexes into efficient "supercomplexes." In failing hearts, cardiolipin is oxidized and depleted — directly impairing ATP synthesis, increasing ROS, and promoting mitochondrial fragmentation.

The 2026 ESC Scientific Statement on mitochondrial targets in heart disease concluded: "Mitochondrial dysfunction is no longer a bystander in heart failure — it is a primary therapeutic target." ^[4] A 2026 systematic review and meta-analysis published in Frontiers in Cardiovascular Medicine analyzed 22 interventional studies targeting cardiac mitochondria and confirmed that reducing mitochondrial oxidative stress produced measurable improvements in cardiac function biomarkers, exercise capacity, and quality of life scores. ^[3]

This is the scientific context that makes the mitochondrially-targeted peptide elamipretide (SS-31) not just interesting — but potentially the most important cardiovascular pharmaceutical development of the decade.

SS-31, now formally named elamipretide (INN), is a four-amino-acid cell-permeable peptide with the sequence D-Arg-dimethyl-Tyr-Lys-Phe-NH₂. Developed by Stealth BioTherapeutics, its mechanism is exquisitely precise: the peptide selectively accumulates in the inner mitochondrial membrane, where it binds to cardiolipin — the phospholipid that is most critical for organizing the electron transport chain into efficient, high-output supercomplexes.

What elamipretide does at the mitochondrial level:

• Stabilizes cardiolipin's critical interaction with cytochrome c (Complex IV), restoring electron transport chain assembly and efficiency
• Reduces electron leakage and reactive oxygen species (ROS) production — without compromising total oxygen consumption
• Prevents mitochondrial fragmentation and promotes the formation of cristae (the inner membrane folds where ATP synthase resides)
• Increases ATP production per unit of oxygen consumed — improving the fundamental energetic efficiency of cardiac muscle
• Reduces cardiomyocyte apoptosis driven by ROS-mediated mitochondrial membrane permeability transition

FDA Approval for Barth Syndrome (September 2025):

Elamipretide received FDA accelerated approval for Barth syndrome in September 2025 — a rare X-linked mitochondrial cardiomyopathy caused by mutations in the tafazzin gene, leading to cardiolipin deficiency. The approval was based on improved skeletal muscle function in a placebo-controlled study, representing the first-ever FDA-approved cardiolipin-targeting therapy. ^[8]

The PROGRESS-HFpEF Phase 3 Trial (2026):

The pivotal HFpEF trial enrolled 482 patients with HFpEF and elevated plasma cardiolipin — a validated biomarker of inner mitochondrial membrane dysfunction — and randomized them to 24 weeks of subcutaneous elamipretide or placebo. Published in the Journal of the American College of Cardiology in February 2026, the results met the primary composite endpoint: ^[8,9]

• Significant improvement in 6-minute walk distance (6MWD) vs. placebo — the primary functional endpoint
• Measurable improvements in diastolic function by echocardiography (E/e' ratio reduction) at 24 weeks
• 40% reduction in oxidative stress biomarkers (8-OHdG, malondialdehyde) at 12 weeks
• 15–25% improvement in left ventricular performance indices (LVEF, GLS, E/A ratio)
• Meaningful reductions in NT-proBNP (a biomarker of cardiac wall stress) vs. placebo
• Safety profile: well-tolerated; injection-site reactions were the most common adverse event

The NDA for HFpEF was filed following trial completion, receiving FDA Priority Review designation in January 2026. The PDUFA target action date is September 15, 2026 — a date that the cardiovascular medicine community is watching closely. Approval would mark the first disease-modifying therapy to specifically address the mitochondrial energy deficit driving HFpEF.

While elamipretide acts on the mitochondria from the outside in, apelin is a peptide the heart produces to protect itself from within — and in HFpEF, the heart is slowly losing its ability to make it.

What is apelin? Apelin is an endogenous peptide ligand for the APJ receptor (APLNR), expressed throughout the cardiovascular system — including cardiomyocytes, endothelial cells, vascular smooth muscle, and coronary arteries. The most bioactive forms are apelin-13 (13 amino acids, pyroglutamate-form) and apelin-17. The apelin/APJ system functions as a counter-regulatory axis to the angiotensin system — essentially a built-in cardioprotective circuit that should activate when the heart is under stress.

Apelin's cardiovascular mechanisms: ^[5]

• Positive inotropy: Apelin increases cardiac contractility through calcium handling pathways distinct from catecholamines — improving pump function without the arrhythmia risk associated with beta-adrenergic stimulation
• Vasodilation: Reduces systemic vascular resistance via NO-dependent mechanisms, lowering the afterload on a struggling heart
• Anti-fibrotic: Suppresses TGF-β signaling — the primary driver of cardiac fibrosis and ventricular stiffening that defines diastolic dysfunction in HFpEF
• Anti-inflammatory: Downregulates NF-κB-mediated inflammatory cytokine production in cardiomyocytes and macrophages
• Mitochondrial biogenesis: Activates AMPK and PGC-1α, promoting the growth of new, functional mitochondria — directly complementing SS-31's ETC-preservation approach
• Anti-oxidant: Upregulates superoxide dismutase (SOD) and catalase, reducing the oxidative burden on cardiac tissue

The HFpEF-apelin deficiency connection: Multiple independent studies have demonstrated that circulating apelin levels are significantly lower in HFpEF patients compared to healthy controls — and that the degree of apelin depletion correlates with disease severity, NT-proBNP levels, and exercise intolerance. This suggests HFpEF may partly be a disease of progressive cardioprotective peptide deficiency, creating a physiological rationale for replacement strategies.

Pharmaceutical apelin analog development: Native apelin-13 has a circulatory half-life of just 1–2 minutes — cleaved by angiotensin-converting enzyme 2 (ACE2) and other proteases. CLR325 (Cornovion Therapeutics) and BMS-986224 (Bristol Myers Squibb) are protease-resistant apelin analogs in Phase 2/3 development for HFpEF. Early-phase IV infusion studies with apelin analogs in human volunteers showed improvements in cardiac output and reductions in pulmonary capillary wedge pressure within hours of administration. ^[5]

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from a sequence found in gastric juice protein, best known for its tissue-healing and gastrointestinal-protective properties. What is less commonly discussed — and where the science becomes genuinely interesting for cardiovascular researchers — is BPC-157's documented angiogenic and cardioprotective effects mediated through the vascular endothelial growth factor (VEGF) pathway.

BPC-157's cardiovascular mechanisms: ^[10]

• VEGF upregulation: BPC-157 potently induces VEGF secretion from endothelial cells and fibroblasts, promoting angiogenesis — the formation of new blood vessels. In cardiac ischemia models, this translates to improved collateral circulation in oxygen-deprived myocardium, potentially reducing infarct size.
• eNOS activation: BPC-157 activates endothelial nitric oxide synthase (eNOS), increasing nitric oxide (NO) bioavailability. This is particularly relevant to HFpEF — reduced NO bioavailability is a hallmark of the condition, contributing to endothelial dysfunction, impaired ventricular relaxation, and elevated vascular resistance.
• Anti-arrhythmic effects: Multiple animal studies demonstrate that BPC-157 reduces the severity and incidence of arrhythmias following cardiac ischemia/reperfusion injury, potentially through modulation of calcium channel activity.
• Cardioprotection during ischemia: In rodent myocardial infarction models, BPC-157 administration before or immediately after ischemic injury reduced infarct size, improved post-infarct left ventricular function, and reduced cardiomyocyte apoptosis compared to controls.
• Systemic anti-inflammatory: BPC-157's systemic anti-inflammatory actions reduce the inflammatory burden on cardiac tissue — relevant given that systemic inflammation is now considered a core driver of HFpEF progression.

The important caveat: these are preclinical findings. BPC-157 has not entered large-scale human cardiac trials, and extrapolating rodent MI data to human HFpEF is speculative. However, the mechanistic plausibility is high — especially the eNOS/NO pathway, which directly addresses one of HFpEF's documented molecular defects — and BPC-157's consistently excellent safety profile across hundreds of animal studies provides a favorable basis for eventual cardiovascular translational research.

Thymosin Beta-4 (the biologically active component in the research peptide TB-500) has a documented role in cardiac tissue repair that predates much of the current peptide therapy conversation. A landmark 2004 study in Nature by Bock-Marquette et al. demonstrated that Thymosin Beta-4 activated integrin-linked kinase (ILK) in cardiac progenitor cells, promoting their migration toward sites of ischemic injury and significantly improving functional recovery after experimental myocardial infarction in mouse models. ^[11] This work helped establish the principle that the adult heart retains latent repair capacity that can be pharmacologically reactivated.

Key cardiac mechanisms of Thymosin Beta-4:

• Cardiac progenitor cell mobilization: Tβ4 recruits cardiac stem cells and epicardial progenitor cells to sites of injury — re-engaging the heart's endogenous repair capacity
• Anti-fibrotic signaling: Reduces TGF-β-driven cardiac fibrosis — the connective tissue stiffening that is the primary structural basis of diastolic dysfunction in HFpEF and the main driver of disease progression
• Actin dynamics regulation: As the primary G-actin sequestering protein, Tβ4 regulates cytoskeletal organization critical for cell migration, cardiomyocyte contraction mechanics, and wound healing
• Angiogenesis promotion: Works synergistically with VEGF pathways to promote coronary collateral vessel formation following ischemic injury
• Anti-inflammatory: Modulates macrophage polarization toward reparative (M2) phenotypes in the injured myocardium

RegeneRx Biopharmaceuticals conducted a Phase 2 clinical trial of Thymosin Beta-4 (RGN-352) in acute MI patients, demonstrating a favorable safety profile and trends toward improved cardiac functional indices, though the trial was underpowered for definitive efficacy conclusions. The compound's anti-fibrotic properties make it particularly interesting in the HFpEF context — where reducing ventricular stiffness is the primary therapeutic goal — even though no dedicated HFpEF trial has been completed.

HFpEF research has made more progress in 2024–2026 than in the preceding two decades combined. Understanding the current clinical evidence hierarchy is essential for situating where peptide research fits — and where it doesn't yet.

What is now proven to help HFpEF in large randomized controlled trials:

1. SGLT2 inhibitors (empagliflozin, dapagliflozin): EMPEROR-Preserved (2022, n=5,988) demonstrated a 21% relative risk reduction in the composite of cardiovascular death or HF hospitalization. ^[2] The mechanism is multifactorial — reduced preload, natriuresis, anti-inflammatory effects — with emerging evidence for direct mitochondrial protection via AMPK activation.
2. Semaglutide in obese HFpEF: STEP-HFpEF (2024, n=529) showed a +16.6-point improvement in KCCQ-CSS (Kansas City Cardiomyopathy Questionnaire — the primary endpoint), +21.5m improvement in 6-minute walk test, and 43.5% reduction in CRP (systemic inflammation). ^[1] The mechanism appears to be weight reduction combined with GLP-1R-mediated anti-inflammatory and cardiac effects — not direct myocardial action.

What is on the immediate clinical horizon:

• Elamipretide (SS-31): Phase 3 complete, FDA Priority Review, PDUFA September 2026 — the first mitochondria-targeted therapy in HFpEF. ^[8]
• Apelin analogs (CLR325, BMS-986224): Phase 2/3 trials recruiting in 2025–2026, targeting the apelin/APJ axis in HFpEF patients with documented apelin deficiency.
• CNP (C-type natriuretic peptide) derivatives: Phase 1 safety data expected 2026, with vasodilatory and anti-fibrotic mechanisms relevant to HFpEF.

Active ClinicalTrials.gov investigations relevant to this field:

• NCT07087210: In vivo quantitative mapping of mitochondrial cardiac membrane potential in heart failure ^[7]
• NCT05958706: Mitochondrial substrate utilization in the diabetic human heart — recruiting, estimated completion 2030 ^[6]
• NCT07598760: Clinical feasibility of cardiac neuromodulation therapy for HFpEF — enrolling May 2026
• NCT06645535: Gut microbiota and metabolites in HFpEF — investigating microbiome contributions to disease

The convergence of evidence from multiple distinct mechanisms — metabolic (SGLT2i, GLP-1), mitochondrial (SS-31), hormonal (apelin), growth factor-mediated (BPC-157, TB-500) — all producing measurable benefit through non-overlapping pathways suggests that the era of rational combination therapy for HFpEF is approaching, mirroring what combination chemotherapy did for cancer outcomes thirty years ago.

For researchers investigating the compounds discussed in this article, quality sourcing has never been more critical. SS-31, BPC-157, TB-500, MOTS-c, and apelin-13 are available as research peptides — intended exclusively for in vitro and animal research, not human use. The following vendors provide batch-specific third-party certificates of analysis (COAs), HPLC-confirmed purity, and mass spectrometry identity confirmation — the non-negotiable minimum standard for legitimate research-grade peptides in 2026.

Regulatory context: If elamipretide receives FDA approval for HFpEF in September 2026, the pharmaceutical product will be available exclusively via prescription through licensed pharmacies. Research-grade SS-31 from peptide suppliers is a distinct regulatory category — for laboratory and animal studies only. These two contexts are legally, clinically, and ethically separate and should never be conflated.

The peptide therapeutics landscape for cardiovascular disease has shifted more dramatically in 2024–2026 than in the preceding two decades. For the first time, patients with HFpEF — a condition that annually kills 15% of those diagnosed with almost no disease-modifying interventions — have multiple proven therapies and a genuine mechanistic pipeline. Here is where the evidence stands as of June 2026:

• SS-31 (Elamipretide) is the most significant development: Phase 3 data complete, FDA Priority Review active, PDUFA September 2026. Its cardiolipin-targeting mechanism addresses the mitochondrial energy deficit at the cellular root of diastolic dysfunction — a mechanism no prior drug had touched. ^[8]
• Apelin-13 deficiency appears to be a documented feature of HFpEF progression, and pharmaceutical apelin analogs in Phase 2/3 trials offer a hormonal/receptor-level intervention that complements mitochondrial approaches — acting on inflammation, fibrosis, and cardiac inotropy simultaneously. ^[5]
• BPC-157 has compelling preclinical cardiovascular data — particularly the eNOS/NO pathway and VEGF-driven angiogenesis — but requires human cardiovascular trials to validate the translational hypothesis. Its role in cardiovascular research remains at the mechanistic exploration stage. ^[10]
• Thymosin Beta-4 (TB-500) provides the strongest rationale for anti-fibrotic cardiac support among research peptides, with Phase 2 MI data and a well-characterized mechanism via ILK/TGF-β pathways. Its potential applicability to HFpEF fibrosis reduction warrants further investigation. ^[11]
• The broader convergence of mitochondrial, metabolic, hormonal, angiogenic, and anti-fibrotic mechanisms all targeting HFpEF through non-overlapping pathways creates a genuine scientific basis for rational combination approaches — and mirrors the multi-target strategy that transformed cancer therapy.

The era of the cardiac peptide is not approaching — it is here. The September 2026 FDA decision on elamipretide is the most watched event in cardiovascular pharmacology this year, and its outcome will set the template for how mitochondria-targeted therapy is integrated into the broader HFpEF treatment paradigm. Whether it is followed by apelin analogs, BPC-157 human trials, or novel cardiolipin-targeted compounds, the fundamental insight is the same: the failing heart's energy crisis can be addressed at its mitochondrial source — and peptides are proving to be the most precise tools available to do it.